|Articles|June 29, 2012

Flaws and All, This Is a Start

My thought is that it is good to move forward. No doubt there will be needed changes, but the status quo is broken.

Michael Glod, MD

My thought is that it is good to move forward. No doubt there will be needed changes, but the status quo is broken and as Roosevelt said during the depression, “Try something. Try anything. And if that doesn’t work, try something else.” Flaws and all, this is a start. Hopefully it won’t result in World War II between the political parties.

More on the Supreme Court Decision

Derek Raghavan

Bruce Minsky

Nora Janjan

Michael Glod

James B. Yu

Lawrence Wagman

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

November 5th, 2026

Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

November 5th, 2026

Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

November 5th, 2026

Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC

Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.

November 5th, 2026

FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC

The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.

November 5th, 2026

Evaluating Factors That Affect HDR Brachytherapy and SBRT Decisions in Radiation Oncology

Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.